Advyser BloodSuite-RHD
Advyser BloodSuite-RHD automates qPCR data analysis, ensuring standardized and traceable results for laboratories.
devyser.comCrawled Nov 9, 2026
Advyser BloodSuite-RHD automates qPCR data analysis, ensuring standardized and traceable results for laboratories.
Devyser Genomic Blood Typing simplifies blood antigen profiling with an all-in-one NGS solution.
Devyser ensures compliance with the In Vitro Diagnostic Medical Devices Regulation (IVDR) for its diagnostic devices.
Devyser Thalassemia v2 offers rapid, comprehensive genetic testing for thalassemia, enhancing detection capabilities with minimal hands-on time and streamlined workflows for efficient lab operations.
Devyser’s Thalassemia v2 NGS assay supports efficient testing for thalassemia and sickle cell disease.
Devyser provides instructions for use and certificates for download.
Devyser offers a webinar on personalized RhD prophylaxis and details breakthroughs in CFTR genotyping and rapid testing.
Devyser enters Strategic Supply Agreement with Illumina to offer sequencing instruments and products
Devyser’s genetic testing solution for thalassemia supports evaluation and research in genetic health.
Microdeletions within the AZF region of Y chromosome
Advyser BloodSuite-RHD includes updates on webinars and blog content.
Devyser News and Press covers research, trends, and developments in the diagnostic industry.
Devyser, founded in 2004 in Stockholm, develops single-tube DNA tests to streamline lab workflows and reduce patient wait times.
Devyser is hiring two research scientists and a senior scientist for its research and development team.
Devyser streamlines lab workflows and supports fast patient diagnosis with DNA test kits that are accurate, quick, and easy to use
Devyser provides CLIA-certified laboratory services using advanced technology and experienced professionals to deliver reliable test results.
Devyser distributes solutions worldwide through direct sales or specialized distributors.
Devyser provides FAQs on products, lab procedures, and technical questions, with contact details at techsupport@devyser.com.
Devyser offers fast, precise, and easy-to-use genetic test solutions for laboratories worldwide.
Devyser does not sell personal information but may share it internally or with affiliates as described in its Privacy Policy.
Devyser Whistleblowing Policy is intended to provide the applicable instructions and information when individuals connected to Devyser wish to report any wrongdoing.
Please find the terms and conditions for different countries and regions below.
Devyser names Torben Thölix as Chief Commercial Officer to lead its global commercial operations. Thölix joins the executive team under CEO Jan Wahlström and begins transitioning into the role in September, with full-time assumption in October. The appointment aims to strengthen Devyser’s commercial strategy and expansion efforts.
Devyser Diagnostics AB reports growth in direct sales markets during Q3 2026. The company expands its product portfolio, launches a new chimerism assay with Thermo Fisher Scientific, secures its first reagent rental agreement with Illumina, and hires a new Chief Commercial Officer. Inventory adjustments at its largest distributor remain a constraint on sales performance.
Devyser expands its **One Lambda™ Devyser Accept cfDNA** test to monitor **heart and lung transplant patients**, complementing its existing kidney transplant application. The IVDR-compliant, blood-based solution—distributed via Thermo Fisher Scientific—now covers all three organ types. The test enables non-invasive tracking of transplant recipients through a single diagnostic platform.
Devyser secures its first commercial reagent rental deal with an Italian lab as part of its Systems Integrator partnership with Illumina. The agreement integrates Illumina’s sequencing hardware with Devyser’s diagnostic assays to broaden access to next-generation sequencing (NGS). This marks a key milestone in the collaboration’s expansion into clinical and research applications.
Devyser Diagnostics AB secures a **SEK 5.7 million** tender from **Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico** in Milan for its **NGS test (Devyser Thalassemia)** and **Amplicon Suite** analysis software. The three-year contract doubles test volumes compared to the prior agreement. The deal expands Devyser’s presence in Italy through its local subsidiary.